Santosh Pillai, DO
Psychiatry · Birmingham, ALNPI 1346405024
Payments from drug & device makers
What this record shows
This record is dominated by other: $17,600 of the $28,236 with a category attached, or 62.3%. Neuronetics, Inc. accounts for 62.7% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2024 at $18,868 and has fallen 92.9% since, to $1,339 in 2025. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 527 payments — averaging $53.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$18K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Sunovion Pharmaceuticals Inc.$849
- Teva Pharmaceuticals USA, Inc.$848
- plus $5K from 31 others
Across 2 payments — averaging $5308.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$10K
- H. Lundbeck A S$617
What the payments were for
- Food & beverage$10,55237%
- Education$810%
- Gifts$20%
- Other$17,60062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$17,600
- ARISTADA$500
- LATUDA$481
- REXULTI$369
- AUSTEDO$257
- ARISTADA INITIO$125
- VRAYLAR$123
- ABILIFY MAINTENA$112
- SPRAVATO$101
How this compares
$28,236 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 35 | $53,781 |
| RexultiBrexpiprazole | 19 | $31,755 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 192 | $6,765 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $5,620 |
| Lisdexamfetamine Dimesylate | 18 | $4,390 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 109 | $4,344 |
| Clonazepam | 237 | $2,757 |
| Alprazolam | 354 | $2,248 |
| Aripiprazole | 61 | $2,040 |
| AmantadineAmantadine Hcl | 22 | $2,019 |
| Lamotrigine | 129 | $1,499 |
| Buspirone Hcl | 173 | $1,350 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 38 | $1,326 |
| Lamotrigine ErLamotrigine | 16 | $1,309 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 36 | $858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,302 | $53,78135 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,023 | $31,75519 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $362 | $5,62015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Birmingham
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Richard SheltonBirmingham$79K
- Melissa KarrhBirmingham$51K
- Matthew MacalusoBirmingham$49K
- Jennifer HadleyBirmingham$27K
- Kerry ClearyBirmingham$12K
- Praveen JettyBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.